This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen
[PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer
undergoing active surveillance. Vaccines made from a person's tumor cells may help the body
build an effective immune response to kill tumor cells that express PSA.
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7